They demonstrated an enhanced anti-tumor effect of these T cells through the direct blockade of CD161, a NK cell receptor expressed on the T cells surface, or by the inactivation of its respective NK gene KLRB1, highlighting the role of CD161 and potential therapeutic intervention [98]. Here, KLRB1 is linked to neoplasm.